Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire.
about
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.Should monitoring of vancomycin be delayed? A case of likely nephrotoxicity occasioned by morbid obesity and minimal monitoring.Vancomycin administration: the impact of multidisciplinary interventionsAssessment of therapeutic drug monitoring of vancomycin in elderly patients according to new guidelines.Are vancomycin trough concentrations adequate for optimal dosing?Therapeutic drug monitoring of anti-infective agents in critically ill patients.Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.Full hydrodynamic reversibility of the weak dimerization of vancomycin and elucidation of its interaction with VanS monomers at clinical concentration.Therapeutic drug monitoring of vancomycin in patients receiving haemodialysis: time for a change.Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats.Antimicrobial resistance (AMR) nanomachines-mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation.
P2860
Q33836490-5B4558BD-467F-49DA-AA35-AA1780B5FF39Q34894900-32F7DE4A-5EBD-4D98-BEDF-F3759F8929A3Q35959546-9ABAB4C4-0436-42F4-8C3A-8D7E16218A52Q36409465-7B387A6A-15CF-4E7E-A9CF-636D4952C11EQ36468173-7657810C-3525-461D-93CE-C4F731F8AA2DQ36733457-C1623EAB-B60E-4B20-A8AD-4FCE4443BCFBQ37453459-AB6EC789-70B7-4932-B0AD-BEF50086761CQ37544400-361BC6F8-9C4A-4882-8451-2AF1DFE25444Q38790740-F8B354E5-23A3-4D59-A355-8EB66FC08CEFQ40749709-702067EF-0753-4699-B1C0-8E0C724B0235Q42079847-5C20E0E6-7720-4FEF-81F8-4EB64BFC05E4Q42835349-3DDBBF0B-FBD8-4219-8AF0-073AEC439E93Q46762962-C0B34E5C-5CB8-4490-8990-B71C8E833C42Q51021470-8F8501C0-841E-4B11-8B39-64204450E6F4Q52360303-3DF7C889-0050-4C2D-80D6-8A1B2D4592DC
P2860
Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Vancomycin therapeutic drug mo ...... tibiotic Assays questionnaire.
@en
Vancomycin therapeutic drug mo ...... rnal Quality Assessment Scheme
@nl
type
label
Vancomycin therapeutic drug mo ...... tibiotic Assays questionnaire.
@en
Vancomycin therapeutic drug mo ...... rnal Quality Assessment Scheme
@nl
prefLabel
Vancomycin therapeutic drug mo ...... tibiotic Assays questionnaire.
@en
Vancomycin therapeutic drug mo ...... rnal Quality Assessment Scheme
@nl
P2093
P356
P1476
Vancomycin therapeutic drug mo ...... tibiotic Assays questionnaire.
@en
P2093
A H Thomson
A P MacGowan
J F Wilson
J M Darville
P304
P356
10.1093/JAC/DKF212
P407
P577
2002-11-01T00:00:00Z